Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Intrauterine Injection of HCG on Pregnancy Outcome in Repeated Implantation Failure Patients
NCT02870855 · Reproductive & Genetic Hospital of CITIC-Xiangya · NA · withdrawn · last registry update 2022-01-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Entry criteria were changed, investigator have registrated a new trials.” | – | Registry record, Reproductive & Genetic Hospital of CITIC-Xiangya |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-22Results posted on the registry: Sierra Oncology LLC - a GSK company, Momelotinib + Placebo to match danazol (NCT04173494)
- 2022-11-30Also stopped (terminated): Assiut University, a drug against PGR (NCT04663568)
- 2022-11-17Phase 3 first posted: Bio Genuine (Shanghai) Biotech Co., Ltd., BG2109 + Placebo for BG2109 (NCT05620355)
- 2022-11-03Results posted on the registry: Milton S. Hershey Medical Center, Naltrexone + Norethindrone Acetate (NCT03970330)
- 2022-11-03Also stopped (terminated): Milton S. Hershey Medical Center, Naltrexone + Norethindrone Acetate (NCT03970330)
- 2022-10-19Phase 3 first posted: Angelica Lindén Hirschberg, Micronized progesterone in continuous combination with oral estrogen + Norethisterone acetate in continuous combination with oral estrogen (NCT05586724)
- 2022-10-19Results posted on the registry: Charles Drew University of Medicine and Science, Mifepristone 600 mg daily + Placebo (NCT03052400)
- 2022-10-10Results posted on the registry: Ampio Pharmaceuticals. Inc., Danazol Capsules + Placebo (NCT01821677)
- 2022-10-06Results posted on the registry: The Scripps Research Institute, Mifepristone 1200 mg daily + Placebo (NCT02179749)
- 2022-10-04Phase 3 first posted: Hua Li, Medroxyprogesterone Acetate 500 MG Oral Tablet (NCT05565573)
- 2022-07-13Results posted on the registry: University of Chicago, enzalutamide + mifepristone (NCT02012296)
- 2022-06-29Results posted on the registry: University of Utah, Copper IUD + Levonorgestrel IUD (NCT02175030)
- 2022-06-08Results posted on the registry: University of California, Davis, Mifepristone 200 MG + Placebo Oral Tablet (NCT03714880)
- 2022-06-08Also stopped (terminated): University of California, Davis, Mifepristone 200 MG + Placebo Oral Tablet (NCT03714880)
- 2022-04-28Results posted on the registry: M.D. Anderson Cancer Center, a drug against PGR (NCT00788671)
- 2022-04-28Results posted on the registry: Bayer, Levonorgestrel IUS (Mirena, BAY86-5028) (NCT02985541)
- 2022-04-20Results posted on the registry: Myovant Sciences GmbH, Relugolix + Estradiol/norethindrone acetate (NCT03103087)
- 2022-04-19Results posted on the registry: Myovant Sciences GmbH, Relugolix + Estradiol/norethindrone acetate (NCT03049735)
- 2022-04-07Phase 3 first posted: Xiaojun Chen, Megestrol Acetate 160 MG Oral Tablet + Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg (NCT05316493)
- 2022-04-04Results posted on the registry: HRA Pharma, Norgestrel 0.075 mg tablets (NCT03559010)
- 2022-04-04Also stopped (terminated): HRA Pharma, Norgestrel 0.075 mg tablets (NCT03559010)
- 2022-03-31Phase 3 first posted: Calcutta National Medical College and Hospital, Mifepristone + Letrozole (NCT05304273)
- 2022-03-16Results posted on the registry: HRA Pharma, CDB-2914 + Levonorgestrel (NCT00551616)
- 2022-03-16Results posted on the registry: Norton Healthcare, Norethindrone acetate (NCT02353247)
- 2022-03-03Phase 3 first posted: Organon and Co, NOMAC-E2 COC (NCT05264506)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision